30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Alaunos Therapeutics Inc (TCRT)

Track

The most recent insider transactions occurred on December 31, 2024, with Jaime Vieser selling shares. Prior to this, Kevin S. Sr. Boyle had planned sales in September 2023. Significant buying activity was noted in November 2022 by Robert W. Postma and Jaime Vieser.
Stock chart
Ticker: TCRT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Vieser Jaime
2 sales — total 6,022 USD
Sale 31 Dec 2024
Value US$2,911,950.01 | Price 233.97 | Shares 1,609
Sale 31 Dec 2024
Value US$167,196.94 | Price 239.02 | Shares 61,112
Planned sale 1 Sep 2023
Value US$4,522,843.51 | Price 48.12 | Shares 11,579
Proposed sale 1 Sep 2023
Value US$1,429,308.08 | Price 219.73 | Shares 70,921
Buy 29 Nov 2022
Value US$487,500.00 | Price 0.65 | Shares 750,000
Buy 29 Nov 2022
Value US$812,500.00 | Price 0.65 | Shares 1,250,000
Buy 17 Nov 2021
Value US$12,762.40 | Price 1.40 | Shares 9,116
Buy 16 Nov 2021
Value US$1,237.60 | Price 1.40 | Shares 884
Buy 29 Sep 2021
Value US$191,000.00 | Price 1.91 | Shares 100,000
Buy 2 Sep 2021
Value US$94,271.16 | Price 1.73 | Shares 54,492
Buy 2 Sep 2021
Value US$35,478.84 | Price 1.73 | Shares 20,508
Planned sale 8 Jan 2021
Value US$87,029.28 | Price 3.12 | Shares 27,894
Planned sale 8 Jan 2021
Value US$55,681.80 | Price 3.09 | Shares 18,020
Planned sale 8 Jan 2021
Value US$82,680.00 | Price 3.12 | Shares 26,500
Planned sale 4 Jan 2021
Value US$58,806.40 | Price 2.72 | Shares 21,620
Planned sale 4 Jan 2021
Value US$286,428.03 | Price 2.71 | Shares 105,693
Planned sale 2 Jan 2020
Value US$101,892.70 | Price 4.55 | Shares 22,394
Planned sale 2 Jan 2020
Value US$127,049.65 | Price 4.55 | Shares 27,923
Planned sale 2 Jan 2020
Value US$113,249.50 | Price 4.55 | Shares 24,890
Planned sale 2 Jan 2020
Value US$76,681.15 | Price 4.55 | Shares 16,853
Planned sale 2 Jan 2020
Value US$98,143.50 | Price 4.55 | Shares 21,570
Planned sale 30 Dec 2019
Value US$540,186.72 | Price 4.88 | Shares 110,694
Planned sale 26 Nov 2019
Value US$61,251.75 | Price 5.25 | Shares 11,667
Buy 8 Nov 2017
Value US$30,139.20 | Price 4.68 | Shares 6,440
Buy 8 Nov 2017
Value US$19,983.60 | Price 4.68 | Shares 4,270
Sale 19 Nov 2015
Value US$1,968,795.72 | Price 12.84 | Shares 153,333
Sale 9 Jun 2015
Value US$506,000.00 | Price 10.12 | Shares 50,000
Sale 4 Jun 2015
Value US$55,743.35 | Price 9.55 | Shares 5,837
Sale 3 Jun 2015
Value US$266,750.00 | Price 9.70 | Shares 27,500
Sale 3 Jun 2015
Value US$32,339.80 | Price 9.70 | Shares 3,334
Sale 3 Jun 2015
Value US$255,993.60 | Price 9.60 | Shares 26,666
Sale 3 Jun 2015
Value US$332,064.36 | Price 9.72 | Shares 34,163
Buy 9 Feb 2015
Value US$12,600,000.00 | Price 8.75 | Shares 1,440,000
Buy 29 Oct 2013
Value US$10,000,000.50 | Price 3.50 | Shares 2,857,143
Buy 20 Jan 2012
Value US$9,999,990.00 | Price 5.20 | Shares 1,923,075
Buy 23 Aug 2011
Value US$191,087.06 | Price 4.99 | Shares 38,294
Buy 22 Aug 2011
Value US$543,988.72 | Price 4.91 | Shares 110,792
Buy 19 Aug 2011
Value US$969,116.16 | Price 4.91 | Shares 197,376
Buy 18 Aug 2011
Value US$759,716.10 | Price 4.95 | Shares 153,478
Buy 10 Aug 2011
Value US$25,925.50 | Price 5.19 | Shares 5,000
Buy 9 Aug 2011
Value US$1,464,707.34 | Price 5.13 | Shares 285,518
Buy 8 Aug 2011
Value US$2,037,605.36 | Price 4.58 | Shares 444,892
Buy 5 Aug 2011
Value US$539,920.80 | Price 4.65 | Shares 116,112
Buy 3 Feb 2011
Value US$10,982,500.00 | Price 5.75 | Shares 1,910,000
Buy 12 Jan 2011
Value US$11,645,928.00 | Price 4.80 | Shares 2,426,235
Buy 9 Dec 2009
Value US$155,000.00 | Price 3.10 | Shares 50,000
Buy 9 Dec 2009
Value US$542,500.00 | Price 3.10 | Shares 175,000
Buy 8 Dec 2009
Value US$399,900.00 | Price 3.10 | Shares 129,000
Buy 15 Sep 2009
Value US$599,997.95 | Price 1.83 | Shares 328,766
Buy 15 Sep 2009
Value US$91,250.00 | Price 1.83 | Shares 50,000
Buy 7 Dec 2007
Value US$8,990.10 | Price 3.00 | Shares 3,000
Buy 15 Mar 2007
Value US$20,000.00 | Price 5.00 | Shares 4,000
Buy 12 Mar 2007
Value US$9,900.00 | Price 4.95 | Shares 2,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-03 2024-12-31 S Sale
1.7
Vieser Jaime
Non-Executive Director
1,609 +49.8%
233.97
US$2,911,950 		1,609 +49.8% 233.97 US$2,911,950
2025-01-03 2024-12-31 S Sale
1.7
Vieser Jaime
Non-Executive Director
61,112 -27.0%
239.02
US$167,197 		61,112 -27.0% 239.02 US$167,197
2023-09-05 2023-09-01 PlS Planned sale
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
11,579 +1.3%
48.12
US$4,522,844 		11,579 +1.3% 48.12 US$4,522,844
2023-09-01 2023-09-01 PrS Proposed sale
0.9
Boyle Kevin S. Sr.

Officer

Officer
70,401
0.14
US$9,504 		70,401 0.14 US$9,504
2022-12-01 2022-11-29 B Purchase
1.9
Postma Robert W
Non-Executive Director
750,000 +17.6%
0.65
US$487,500 		750,000 +17.6% 0.65 US$487,500
2022-12-01 2022-11-29 B Purchase
1.7
Vieser Jaime
Non-Executive Director
1,250,000 +inf%
0.65
US$812,500 		1,250,000 +inf% 0.65 US$812,500
2021-11-17 2021-11-17 B Purchase
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
9,116 +1.0%
1.40
US$12,762 		9,116 +1.0% 1.40 US$12,762
2021-11-17 2021-11-16 B Purchase
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
884 +0.1%
1.40
US$1,238 		884 +0.1% 1.40 US$1,238
2021-10-04 2021-09-29 B Purchase
1.7
Vieser Jaime
Non-Executive Director
100,000 +16.5%
1.91
US$191,000 		100,000 +16.5% 1.91 US$191,000
2021-09-03 2021-09-02 B Purchase
1.9
Postma Robert W
Non-Executive Director
54,492 +1.3%
1.73
US$94,271 		54,492 +1.3% 1.73 US$94,271
2021-09-03 2021-09-02 B Purchase
1.9
Postma Robert W
Non-Executive Director
20,508 +1.7%
1.73
US$35,479 		20,508 +1.7% 1.73 US$35,479
2021-01-12 2021-01-08 PlS Planned sale
Buck Jill

EVP, GM Gene Therapy

Officer
27,894 -12.3%
3.12
US$87,029 		27,894 -12.3% 3.12 US$87,029
2021-01-12 2021-01-08 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO

Officer
18,020 -22.0%
3.09
US$55,682 		18,020 -22.0% 3.09 US$55,682
2021-01-12 2021-01-08 PlS Planned sale
Hadfield Robert

General Counsel and Secretary

Officer
26,500 -16.6%
3.12
US$82,680 		26,500 -16.6% 3.12 US$82,680
2021-01-06 2021-01-04 PlS Planned sale
De Groot Eleanor

EVP, GM Cell Therapy

Officer
21,620 -9.5%
2.72
US$58,806 		21,620 -9.5% 2.72 US$58,806
2021-01-06 2021-01-04 PlS Planned sale
Cooper Laurence James Neil

President and CEO

Executive Director
105,693 -5.5%
2.71
US$286,428 		105,693 -5.5% 2.71 US$286,428
2020-01-03 2020-01-02 PlS Planned sale
MAUNEY DAVID M MD

President

Officer
22,394 -10.3%
4.55
US$101,893 		22,394 -10.3% 4.55 US$101,893
2020-01-03 2020-01-02 PlS Planned sale
Buck Jill

EVP, GM Gene Therapy

Officer
27,923 -13.8%
4.55
US$127,050 		27,923 -13.8% 4.55 US$127,050
2020-01-03 2020-01-02 PlS Planned sale
De Groot Eleanor

EVP, GM Cell Therapy

Officer
24,890 -12.5%
4.55
US$113,250 		24,890 -12.5% 4.55 US$113,250
2020-01-03 2020-01-02 PlS Planned sale
Hadfield Robert

General Counsel and Secretary

Officer
16,853 -14.3%
4.55
US$76,681 		16,853 -14.3% 4.55 US$76,681
2020-01-03 2020-01-02 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO

Officer
21,570 -25.2%
4.55
US$98,144 		21,570 -25.2% 4.55 US$98,144
2019-12-31 2019-12-30 PlS Planned sale Cooper Laurence James Neil

Chief Executive Officer

Executive Director
110,694 -6.0%
4.88
US$540,187 		110,694 -6.0% 4.88 US$540,187
2019-11-27 2019-11-26 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO
11,667 -12.0%
5.25
US$61,252 		11,667 -12.0% 5.25 US$61,252
2017-11-09 2017-11-08 B Purchase Cooper Laurence James Neil

Chief Executive Officer
6,440 +0.6%
4.68
US$30,139 		6,440 +0.6% 4.68 US$30,139
2017-11-09 2017-11-08 B Purchase MAUNEY DAVID M MD

EVP and Chief Business Officer
4,270 +7.9%
4.68
US$19,984 		4,270 +7.9% 4.68 US$19,984
2015-11-23 2015-11-19 S Sale BELBEL CAESAR J

COO, CLO, and Secretary

Officer
153,333 -72.1%
12.84
US$1,968,796 		153,333 -72.1% 12.84 US$1,968,796
2015-06-11 2015-06-09 S Sale LEBEL FRANCOIS

Executive Vice President R&D

Officer
50,000 -100.0%
10.12
US$506,000 		50,000 -100.0% 10.12 US$506,000
2015-06-05 2015-06-04 S Sale BRENNAN MURRAY Non-Executive Director
5,837 -31.8%
9.55
US$55,743 		5,837 -31.8% 9.55 US$55,743
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
27,500 -100.0%
9.70
US$266,750 		27,500 -100.0% 9.70 US$266,750
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
3,334 -100.0%
9.70
US$32,340 		3,334 -100.0% 9.70 US$32,340
2015-06-05 2015-06-03 S Sale BRENNAN MURRAY Non-Executive Director
34,163 -65.1%
9.72
US$332,064 		34,163 -65.1% 9.72 US$332,064
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
26,666 -100.0%
9.60
US$255,994 		26,666 -100.0% 9.60 US$255,994
2015-02-10 2015-02-09 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,440,000 +8.8%
8.75
US$12,600,000 		1,440,000 +8.8% 8.75 US$12,600,000
2013-10-31 2013-10-29 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
2,857,143 +21.1%
3.50
US$10,000,000 		2,857,143 +21.1% 3.50 US$10,000,000
2012-01-23 2012-01-20 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,923,075 +24.1%
5.20
US$9,999,990 		1,923,075 +24.1% 5.20 US$9,999,990
2011-08-25 2011-08-23 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
38,294 +2.9%
4.99
US$191,087 		38,294 +2.9% 4.99 US$191,087
2011-08-22 2011-08-22 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
110,792 +9.3%
4.91
US$543,989 		110,792 +9.3% 4.91 US$543,989
2011-08-22 2011-08-19 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
197,376 +19.7%
4.91
US$969,116 		197,376 +19.7% 4.91 US$969,116
2011-08-22 2011-08-18 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
153,478 +18.1%
4.95
US$759,716 		153,478 +18.1% 4.95 US$759,716
2011-08-11 2011-08-10 B Purchase Fowler Wyche Non-Executive Director
5,000 +7.4%
5.19
US$25,926 		5,000 +7.4% 5.19 US$25,926
2011-08-09 2011-08-09 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
285,518 +50.9%
5.13
US$1,464,707 		285,518 +50.9% 5.13 US$1,464,707
2011-08-09 2011-08-08 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
444,892 +383.2%
4.58
US$2,037,605 		444,892 +383.2% 4.58 US$2,037,605
2011-08-09 2011-08-05 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
116,112 +inf%
4.65
US$539,921 		116,112 +inf% 4.65 US$539,921
2011-02-07 2011-02-03 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,910,000 +31.5%
5.75
US$10,982,500 		1,910,000 +31.5% 5.75 US$10,982,500
2011-01-14 2011-01-12 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
2,426,235 +inf%
4.80
US$11,645,928 		2,426,235 +inf% 4.80 US$11,645,928
2009-12-11 2009-12-09 B Purchase MCINERNEY TIMOTHY Non-Executive Director
50,000 +31.6%
3.10
US$155,000 		50,000 +31.6% 3.10 US$155,000
2009-12-11 2009-12-09 B Purchase CANNON JAMES ANTHONY Non-Executive Director
175,000 +388.9%
3.10
US$542,500 		175,000 +388.9% 3.10 US$542,500
2009-12-10 2009-12-08 B Purchase ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
129,000 +5.8%
3.10
US$399,900 		129,000 +5.8% 3.10 US$399,900
2009-12-10 2009-09-15 B Purchase ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
328,766 +17.2%
1.83
US$599,998 		328,766 +17.2% 1.83 US$599,998
2009-09-17 2009-09-15 B Purchase MCINERNEY TIMOTHY Non-Executive Director
50,000 +63.9%
1.83
US$91,250 		50,000 +63.9% 1.83 US$91,250
2007-12-10 2007-12-07 B Purchase LEWIS JONATHAN

CEO

Executive Director
3,000 +150.0%
3.00
US$8,990 		3,000 +150.0% 3.00 US$8,990
2007-03-22 2007-03-15 B Purchase MCINERNEY TIMOTHY Non-Executive Director
4,000 +6.8%
5.00
US$20,000 		4,000 +6.8% 5.00 US$20,000
2007-03-14 2007-03-12 B Purchase LEWIS JONATHAN

CEO

Executive Director
2,000 +inf%
4.95
US$9,900 		2,000 +inf% 4.95 US$9,900
Explore more

More insider trading research around Alaunos Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America